What is Open Orphan plc?
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.
OPORF · Verdict
Strong reward · moderate risk
OPORF stands out on valuation and balance sheet, but watch the volatility signal.
Based on 88% data coverage
OPORF · Verdict
P/E 12.1×
Interest covered 14.9×
17% net margin · 13% ROE
Revenue +19.4% CAGR
13% free-cash-flow margin
Below average
Model-based scoring. For information only — not financial advice.
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 59.17M, and a P/E ratio of 8.6x.
The scoring profile indicates a strong reward potential, driven primarily by valuation and profitability. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.